XML 56 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events On October 22, 2015, the FDA and the Taiwan Food and Drug Administration approved the use of MM-398 in combination with 5-FU and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy in the United States and Taiwan, respectively. In October 2015, the Company earned a $47.5 million milestone under the Baxalta Agreement related to the enrollment of the first patient in a Phase 2 clinical trial of MM-398 in front-line pancreatic cancer.